Mutant KRAS drives aberrant RNA modification in colorectal cancer

◇ RESEARCH

In isogenic cell and animal models, mutant KRAS—present in 40-50% of CRC patients—upregulates m6A mRNA modification by stabilizing the METTL3 protein and inhibiting its degradation via p62-driven selective autophagy. (Adv Sci)